Brexucabtagene autoleucel

TECARTUS 0,4 - 2 x 10e8 CELULAS DISPERSION PARA PERFUSION

1 × 10e6 a 2 x 10e6 CELULAS dispersion para perfusionSpainMarketedAuthorised 27 Dec 2020

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

TecartusEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Brexucabtagene autoleucel

TECARTUS 0,4 - 2 x 10e8 CELULAS DISPERSION PARA PERFUSION

1 × 10e6 a 2 x 10e6 CELULAS dispersion para perfusionSpainMarketedAuthorised 27 Dec 2020

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Authorised centrally in the EU

This national listing belongs to a medicine the European Commission authorised for the whole EU.

TecartusEuropean UnionAuthorised

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Tecartus 0.4-2.0 x 10^8 cellen, dispersie voor infusieNetherlands · Oplossing voor infusie · Kite Pharma EU B.V.

TecartusUnited States · 210^6 CAR-positive viable T cells per kg body weight · For Injection · Kite Pharma, Inc.

Packs

Pack	Code	Status
TECARTUS 0,4 - 2 x 10e8 CELULAS DISPERSION PARA PERFUSION, 1 bolsa de 68 ml	729969

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Brexucabtagene autoleucel
Strength: 1 × 10e6 a 2 x 10e6 CELULAS
Dosage form: dispersion para perfusion
Route: vía intravenosa
Register: Spain (AEMPS)
Status: Marketed
Status in the register: Autorizado, comercializado
Authorised: 27 Dec 2020
Registration: 1201492001
Marketing authorisation holder: Kite Pharma Eu B.V.
Procedure: EU centralised
Supply: Uso Hospitalario
EU number: EU/1/20/1492